AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo-Reference-Cited by-全球学者库

AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo

Published:2011-07-18 Issue:7 Volume:6 Page:e21487
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Xie Hua,Lin Liping,Tong Linjiang,Jiang Yong,Zheng Mingyue,Chen Zhuo,Jiang Xiaoyan,Zhang Xiaowei,Ren Xiaowei,Qu Wenchao,Yang Yang,Wan Hua,Chen Yi,Zuo Jianping,Jiang Hualiang,Geng Meiyu,Ding Jian

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference37 articles.

1. The ErbB signaling network: receptor heterodimerization in development and cancer.;MA Olayioye;Embo J,2000

2. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.;D Graus-Porta;Embo J,1997

3. The pathway to signal achievement.;SE Egan;Nature,1993

4. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors.;P Hu;Mol Cell Biol,1992

5. The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.;MM Moasser;Cancer Res,2001

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the role of MGMT and DAPK hypermethylation in response to anti‐EGFR agents: Molecular insights for advancing HNSCC treatment;Head & Neck;2023-12-14

2. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors;Current Topics in Medicinal Chemistry;2023-12

3. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials;Signal Transduction and Targeted Therapy;2023-09-06

4. Synthesis of novel pyrimido[4,5‐b]quinolines as potential anticancer agents and HER2 inhibitors;Chemical Biology & Drug Design;2023-08

5. The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers;Heliyon;2022-08